Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study-Reference-Cited by-同舟云学术

Assay Harmonization and Use of Biological Standards To Improve the Reproducibility of the Hemagglutination Inhibition Assay: a FLUCOP Collaborative Study

Published:2021-08-25 Issue:4 Volume:6 Page:
ISSN:2379-5042
Container-title:mSphere
language:en
Short-container-title:mSphere

Author:

Waldock Joanna¹,Zheng Lingyi²,Remarque Edmond J.³,Civet Alexandre⁴,Hu Branda²,Jalloh Sarah Lartey⁵,Cox Rebecca Jane⁵,Ho Sammy⁶,Hoschler Katja⁶,Ollinger Thierry⁷,Trombetta Claudia Maria⁸,Engelhardt Othmar G.¹,Caillet Catherine²^ORCID

Affiliation:

1. National Institute for Biological Standards and Control, Potters Bar, United Kingdom

2. Sanofi Pasteur, Swiftwater, Pennsylvania, USA

3. Biomedical Primate Research Centre, Rijswijk, The Netherlands

4. Quinten, Paris, France

5. Influenza Centre, Department of Clinical Sciences, University of Bergen, Bergen, Norway

6. Public Health England, Colindale, United Kingdom

7. GSK, Wavre, Belgium

8. University of Siena, Department of Molecular and Developmental Medicine, Siena, Italy

Abstract

The hemagglutination inhibition (HAI) assay is the most commonly used serology assay to detect antibodies from influenza vaccination or influenza virus infection. This assay has been used for decades but requires improved standardization of procedures to provide meaningful data.

Funder

Innovative Medicines Initiative Joint Undertaking

European Union Seventh Framework Programme

European Federation of Pharmaceutical Industries and Associations

Publisher

American Society for Microbiology

Subject

Molecular Biology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mSphere.00567-21

Reference15 articles.

1. World Health Organization. 2018. Influenza (seasonal). WHO fact sheet. World Health Organization Geneva Switzerland. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal).

2. The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses

3. Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future

4. Reproducibility of Serologic Assays for Influenza Virus A (H5N1)

5. Influenza serological studies to inform public health action: best practices to optimise timing, quality and reporting

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of Influenza B/Yamagata Viruses From Season 2012/2013 to 2021/2022 in Italy as an Indication of a Potential Lineage Extinction;Influenza and Other Respiratory Viruses;2024-09

2. Unravelling influenza correlates of protection: lessons from human A/H1N1 Challenge;mBio;2024-05-08

3. Evaluation of Vaccine Immunogenicity—Correlates to Real-World Protection: Influenza;Viruses;2024-03-12

4. 2023 White Paper on Recent Issues in Bioanalysis: ISR for ADA Assays, the Rise of dPCR vs qPCR, International Reference Standards for Vaccine Assays, Anti-AAV TAb Post-Dose Assessment, NanoString Validation, ELISpot as Gold Standard (Part 3 – Recommendations on Gene Therapy, Cell Therapy, Vaccines Immunogenicity & Technologies; Biotherapeutics Immunogenicity & Risk Assessment; ADA/NAb Assay/Reporting Harmonization);Bioanalysis;2024-02-22

5. A TLR9 agonist synergistically enhances protective immunity induced by an Alum-adjuvanted H7N9 inactivated whole-virion vaccine;Emerging Microbes & Infections;2023-08-28